Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (361-370 of 662) with videos related to

Pageof 67
Sort By:
Haematologica|October 14, 2011
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinHarald Herrmann, Sabine Cerny-Reiterer, Karoline V Gleixner, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Scandinavian Journal of Immunology|February 24, 2021
Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKIHarald Renz, Claus Bachert, Claudia Berek, et al.
Blood|September 29, 2005
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsKaroline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, et al.
Oncotarget|December 20, 2012
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AMLHarald Herrmann, Katharina Blatt, Junwei Shi, et al.
Cancer Research|October 19, 2005
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compoundsKarl J Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
Blood|October 24, 2009
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugsKarl J Aichberger, Karoline V Gleixner, Irina Mirkina, et al.
Leukemia|July 10, 2025
ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implicationsJessica Atkins, Anna-Mariya Kukuyan, Monika Toma, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Pageof 67

Showing results (361-370 of 662) with videos related to

Sort By:
Pageof 67
Haematologica|October 14, 2011
CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicinHarald Herrmann, Sabine Cerny-Reiterer, Karoline V Gleixner, et al.
Annals of Hematology|April 3, 2023
Response and resistance to cladribine in patients with advanced systemic mastocytosis: a registry-based analysisJohannes Lübke, Nicole Naumann, Georgia Metzgeroth, et al.
Scandinavian Journal of Immunology|February 24, 2021
Physiology and pathology of eosinophils: Recent developments: Summary of the Focus Workshop Organized by DGAKIHarald Renz, Claus Bachert, Claudia Berek, et al.
Blood|September 29, 2005
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effectsKaroline V Gleixner, Matthias Mayerhofer, Karl J Aichberger, et al.
Oncotarget|December 20, 2012
Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AMLHarald Herrmann, Katharina Blatt, Junwei Shi, et al.
Cancer Research|October 19, 2005
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compoundsKarl J Aichberger, Matthias Mayerhofer, Maria-Theresa Krauth, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
Blood|October 24, 2009
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugsKarl J Aichberger, Karoline V Gleixner, Irina Mirkina, et al.
Leukemia|July 10, 2025
ADH5/ALDH2 dehydrogenases and DNA polymerase theta protect normal and malignant hematopoietic cells from formaldehyde challenge: therapeutic implicationsJessica Atkins, Anna-Mariya Kukuyan, Monika Toma, et al.
Blood|April 21, 2017
Response and progression on midostaurin in advanced systemic mastocytosis: <i>KIT</i> D816V and other molecular markersMohamad Jawhar, Juliana Schwaab, Nicole Naumann, et al.
Pageof 67